Wegovy Pill Approval Strengthens Novo Nordisk
Wegovy pill approval opens a U.S. commercial path as a $149 monthly cash price and U.S. production reshape insurer coverage and investor positioning.
KEY TAKEAWAYS
- FDA approved the Wegovy pill, clearing a U.S. launch for oral semaglutide.
- OASIS 4 showed mean weight loss of 16.6% by the trial-product estimand.
- Company set a $149 monthly cash price and plans U.S. pharmacy and telehealth distribution.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Novo Nordisk said in press releases on Dec. 22, 2025, that FDA approval of the Wegovy pill clears the way for a U.S. launch in early January 2026 and expands the company’s obesity-treatment options.
Approval and Clinical Data
The FDA approved the first oral GLP-1 receptor agonist for chronic weight management: a once-daily oral semaglutide 25 mg pill. It is indicated, alongside diet and exercise, to reduce excess body weight and maintain weight loss in adults with obesity or overweight and established cardiovascular disease. The label also covers reducing major adverse cardiovascular events (MACE), including death, nonfatal myocardial infarction, and stroke.
Novo Nordisk cited the OASIS 4 trial, a 64-week, phase 3, double-blind, placebo-controlled study of 307 adults without diabetes randomized 2:1. Participants had a baseline weight of about 235 pounds. The trial showed mean weight loss of 16.6% by the trial-product estimand and 13.6% by the treatment-policy estimand, compared with about 2.7%–2.4% for placebo. Approximately 76% of those on Wegovy achieved at least 5% weight loss versus 31% on placebo.
The safety profile mirrors that of the injectable Wegovy, with nausea, diarrhea, and vomiting as the most common adverse events. The label includes a boxed warning for thyroid C-cell tumors based on rodent data and contraindications such as medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2. The product is not approved for those under 18, and breastfeeding is not recommended.
Launch and Commercial Implications
Novo Nordisk plans to distribute the pill in the U.S. through pharmacies and telehealth channels. It will be manufactured in North Carolina, with supply already available. The company set the Wegovy price at $149 per month for a 1.5 mg starting dose for cash-paying U.S. consumers and will offer savings programs to qualifying patients. Pricing for higher doses has not been disclosed.
The approval broadens Novo Nordisk’s commercial options in the oral GLP-1 segment and positions the company to compete with Eli Lilly and other oral candidates under regulatory review. Novo Nordisk submitted the oral semaglutide 25 mg application to the European Medicines Agency and other regulators in the second half of 2025. The company provided no quantitative U.S. sales or revenue guidance.
Mike Doustdar, president and chief executive, said, "The pill is here."
